Enrichment of T-cell proliferation and memory gene signatures of CD79A/CD40 costimulatory domain potentiates CD19CAR-T cell functions
暂无分享,去创建一个
S. Sangkhathat | S. Terakura | J. Julamanee | Pongsakorn Choochuen | W. Khopanlert | K. Maneechai | Socheatraksmey Ung | S. Ung
[1] Xingxu Huang,et al. IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors. , 2021, Cancer letters.
[2] J. Leitner,et al. Composite CD79A/CD40 costimulatory endodomain enhances CD19CAR-T cell proliferation and survival. , 2021, Molecular therapy : the journal of the American Society of Gene Therapy.
[3] Yiping Fan,et al. MyD88/CD40 signaling retains CAR T cells in a less differentiated state , 2020, JCI insight.
[4] H. Einsele,et al. BATF3 programs CD8+ T cell memory , 2020, Nature Immunology.
[5] A. Regev,et al. A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.
[6] C. June,et al. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling , 2020, Science Signaling.
[7] K. Oestreich,et al. Ikaros Zinc Finger Transcription Factors: Regulators of Cytokine Signaling Pathways and CD4+ T Helper Cell Differentiation , 2019, Front. Immunol..
[8] J. Vilo,et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update) , 2019, Nucleic Acids Res..
[9] M. Milone,et al. An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer , 2019, American journal of hematology.
[10] Wei-Chun Chang,et al. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies , 2019, Leukemia.
[11] Ke Liu,et al. FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia , 2018, Clinical Cancer Research.
[12] Qing Zhang,et al. Chimeric Antigen Receptor-T Cells with 4-1BB Co-Stimulatory Domain Present a Superior Treatment Outcome than Those with CD28 Domain Based on Bioinformatics , 2018, Acta Haematologica.
[13] Yongliang Zhang,et al. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs. , 2018, JCI insight.
[14] Hans Bitter,et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia , 2018, Nature Medicine.
[15] Stephen J. Schuster,et al. Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas , 2017, The New England journal of medicine.
[16] Michel Sadelain,et al. Therapeutic T cell engineering , 2017, Nature.
[17] T. Sparwasser,et al. Metabolic pathways in T cell activation and lineage differentiation. , 2016, Seminars in immunology.
[18] D. Maloney,et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo , 2015, Leukemia.
[19] C. June,et al. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. , 2016, Immunity.
[20] M. Sadelain,et al. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. , 2015, Cancer cell.
[21] Michel Sadelain,et al. The pharmacology of second-generation chimeric antigen receptors , 2015, Nature Reviews Drug Discovery.
[22] R. Kaplan,et al. 4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors , 2015, Nature Medicine.
[23] J. Rathmell,et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. , 2014, Cell metabolism.
[24] Linda V. Sinclair,et al. Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation , 2013, Nature Immunology.
[25] D. Sabatini,et al. mTOR Signaling in Growth Control and Disease , 2012, Cell.
[26] C. Turtle,et al. Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. , 2012, Blood.
[27] D. Green,et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. , 2011, Immunity.
[28] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[29] C. Thompson,et al. The CD28 signaling pathway regulates glucose metabolism. , 2002, Immunity.
[30] Chi V. Dang,et al. c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism , 1999, Molecular and Cellular Biology.